By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success.
In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments into, and timings of, pre-commercial activities. We surveyed 42 senior stakeholders in director-level roles or higher from both biopharmaceutical companies and investment firms, including private equity, venture capital, investment banking, and business development and licensing (BD&L).
Alexander Fink, Jackson Carroll, Dr. Tony Xu, Herman Sanchez